Nature Reviews Cancer contents July 2014 Volume 14 Number 7 pp447-509

If you are unable to see the message below, click here to view.

Advertisement
The LightCycler® 96 Real-Time PCR System Innovative. Intuitive. Accurate. Now with HRM. Innovative optics for accurate results: Simultaneously capture 96 wells of data for maximum well-to-well consistency. Intuitive touchscreen interface and powerful data analysis software: Speed time to results with an advanced, easy-to-use system. Fast, precise HRM with more data points per °C: Detect all sequence variants, including class III SNPs, in less than 90 minutes. To learn more, please visit www.lightcycler96.com
TABLE OF CONTENTS
July 2014 Volume 14 Number 7		Advertisement
Impact Factor 35 *	In this issue Comment Research Highlights Reviews Perspectives Also this month Article series: Clinical insights Featured article: Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond Matthew Holderfield, Marian M. Deuker, Frank McCormick & Martin McMahon	Cancer Metabolism Webinar Available On Demand Seahorse Bioscience presents: Understanding the tumor micro environment, and its effect on tumor metabolism, progression and therapy. Watch this On Demand webinar presented by Robert Gillies, Ph.D., Moffit Cancer Center. Watch this webinar: www.seahorsebio.com/aacretoc
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Cancer Pharmacogenomics and Targeted Therapies (17-19 September 2014)  Wellcome Trust Genome Campus, Hinxton, UK This 2nd conference will again bring together leading scientists and clinicians to focus on the key challenges in the design, development and clinical implementation of targeted cancer therapies. Abstracts/Bursaries Deadline: 11 July. Registration Deadline: 28 July.
Advertisement
Nature Outlook Cancer Cancer kills millions of people across the globe every year. But the development of targeted medicines, novel drug delivery technologies and clinical research data offer a glimpse towards a cancer-free future.  Access the Outlook free online for six months.  Produced with support from Celgene Corporation.
Article series: Clinical insights Comment: Paraneoplasia, cancer development and immunity: what are the connections? Louis Chesler p447 | doi:10.1038/nrc3766 Chesler discusses immune-mediated paraneoplasias as evidence of the fundamental relationship between cancer and the immune system. Abstract | Full Text | PDF
RESEARCH HIGHLIGHTS Top Microenvironment: An exercise in restraint p449 | doi:10.1038/nrc3769 Two papers in Cancer Cell report the surprising findings that some components of the pancreatic cancer microenvironment suppress, rather than promote, tumour progression. PDF Genomic instability: Transcript elongation: pause at your peril p450 | doi:10.1038/nrc3768 The DNA helicase RECQL5 has a role in moderating transcription stress levels and consequently in suppressing chromosomal breaks. PDF Signalling: FOXM1 and CENPF: co-pilots driving prostate cancer p450 | doi:10.1038/nrc3772 Aytes et al. identify forkhead box M1 (FOXM1) and centromere protein F (CENPF) as synergistic drivers and prognostic markers of prostate cancer. PDF Immunotherapy: Two hits are better than one p451 | doi:10.1038/nrc3777 Highfill et al. find that blocking CXCR2 prevents MDSCs from infiltrating embryonal rhabdomyosarcomas, which improves the response to immune checkpoint blockade. PDF Glioblastoma: Cancer stem cell knockout p452 | doi:10.1038/nrc3771 Ablation of cancer stem cells in established glioblastomas in mice by knockout of the nuclear receptor tailless (Tlx) has therapeutic benefit, and TLX may have a similar role in human glioblastoma stem cells. PDF Drug resistance: Overcoming resistance in acute myeloid leukaemia treatment p452 | doi:10.1038/nrc3776 A new study shows that the sonic hedgehog factor glioma-associated oncogene (GLI1) underlies resistance to two anticancer drugs. PDF IN BRIEF Therapy: Targeting nucleotide synthesis in MYC-driven lymphoma | Tumorigenesis: Mutation versus deletion | Cancer risk: Sexually transmitted cancer risk? | Therapy: Small but loaded | Signalling: Isoform-specific survival | Regenerative medicine: Cause for concern? | Tumorigenesis: Splitting the jaw PDF Cancer JOBS of the week Postdoctoral Position at UT Southwestern Medical Center: Osteoporosis and Cancer University of Texas Southwestern Medical Center (UTSW) PhD Studentship - Novel Gallium-68 Probes for Cancer Imaging University of Hull Postdoctoral Fellow - Stem Cells and Cancer Albert Einstein College of Medicine in New York Postdoctoral Scholar in Cancer and RNA Research Northwestern University- Feinberg School of Medicine Postdoctoral Fellow, Cancer and Stem Cell Biology University of Pennsylvania More Science jobs from Cancer EVENT The 2015 Controlling Cancer Summit 12.05.15 London, UK More science events from
REVIEWS		Top
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond Matthew Holderfield, Marian M. Deuker, Frank McCormick & Martin McMahon p455 | doi:10.1038/nrc3760 Mutations in the RAF family have been associated with several types of cancer, with BRAF mutations being the most common. This led to the development of BRAF inhibitors, which initially improve clinical responses but frequently induce more aggressive, drug-resistant disease and secondary tumours. This Review discusses what we know about RAF mutants in cancer and the lessons learned about acquired drug resistance, especially feedback signalling and the effects of dosing regimens. Abstract | Full Text | PDF
Stem cell dynamics in homeostasis and cancer of the intestine Louis Vermeulen & Hugo J. Snippert p468 | doi:10.1038/nrc3744 This Review discusses recent studies that offer quantitative insights into the dynamics of intestinal stem cell behaviour that govern homeostasis. These studies provide the necessary baseline parameters such that we can begin to understand stem cell behaviour during colorectal cancer development. Abstract | Full Text | PDF | Supplementary information
Imaging preclinical tumour models: improving translational power Marion de Jong, Jeroen Essers & Wytske M. van Weerden p481 | doi:10.1038/nrc3751 de Jong et al. provide an overview of recent developments in molecular imaging and oncological animal models in basic and translational cancer research, with an emphasis on how to improve the translational value of preclinical imaging studies. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION Tumour cell invasion: an emerging role for basal epithelial cell extrusion Gloria M. Slattum & Jody Rosenblatt p495 | doi:10.1038/nrc3767 Normal epithelia can use apical cell extrusion to remove cells without disrupting their barrier function. However, oncogenic mutations can shift extrusion basally, and this Opinion article asks whether this might promote cell invasion and metastasis. Abstract | Full Text | PDF
OPINION New PARP targets for cancer therapy Sejal Vyas & Paul Chang p502 | doi:10.1038/nrc3748 The poly(ADP-ribose) polymerase (PARP) family comprises 17 enzymes, which generate poly(ADP-ribose) and/or mono(ADP-ribose) (MAR) that can modify target protein function and can function as a signalling scaffold. These modifications may have various roles in cancer and, as discussed in this Opinion article, inhibitors of MARylation in particular may warrant investigation as anticancer drugs. Abstract | Full Text | PDF
Advertisement
nature.com webcasts Macmillan Science Communication presents a custom webcast on: Biomarker discovery: Translating proteomics into clinical diagnostics  Now available on demand  Sponsored by:
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2012 Journal Citation Report (Thomson Reuters, 2013)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.